ClinicalTrials.gg
CompletedNCT06671405Updated Apr 27, 2025

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

A Phase 1 interventional study of AZD0780 and Itraconazole in Dyslipidaemia, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
6th of 11
59 · median 59
Started
2024
with 3 others
Phase 1
8 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 6th largest by enrollment, is one of 4 that started in 2024, is one of 8 in phase 1, and was the 5th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.

Read the detailed description

The purpose of this study is to quantify the effect of itraconazole, a strong CYP3A inhibitor, and carbamazepine, a strong CYP3A inducer, on the PK of AZD0780 in healthy participants. This study will also evaluate AZD0780 as a precipitant of CYP3A4 mediated DDI by examining the PK of midazolam (a CYP3A4 substrate) and EE and LNG (CYP3A4 substrates) alone and in combination with AZD0780 in healthy participants.

The study duration (including screening period) will be approximately 9 to 10 weeks for Part 1, 12 to 14 weeks for Part 2, 6 to 8 weeks for Part 3, and 8 to 10 weeks for Part 4 (optional).

Study visits and treatment:

  • Part 1: Participants who are eligible to participate in this study will stay at the Clinical Unit from Day -1 to Day 24 and return to the Clinical Unit again for a Follow-up Visit, 7 to 14 days after the last PK sample.
  • Part 2: Participants who are eligible to participate in this study will stay at the Clinical Unit from Day -1 to Day 37 and return to the Clinical Unit again for a Follow-up Visit, 7 to 14 days after the last PK sample.
  • Part 3: Participants who are eligible to participate in this study will stay at the Clinical Unit from Day -1 to Day 12 and return to the Clinical Unit again for a Follow-up Visit, 7 to 14 days after the last PK sample.
  • Part 4 (optional): Participants who are eligible to participate in this study will stay at the Clinical Unit from Day -1 to Day 22 and return to the Clinical Unit again for a Follow-up Visit, 7 to 14 days after the last PK sample.

Number of Participants:

Approximately 78 participants will be enrolled in this study; 18 participants in Part 1 (itraconazole Cohort), 24 participants in Part 2 (carbamazepine Cohort), 18 participants in Part 3 (midazolam Cohort), and 18 Participants in Part 4 (EE and LNG Cohort) (optional).

03

Conditions studied

  • Dyslipidaemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study-specific procedures.
  2. Healthy male and female participants of non- aged 18 to 75 years with suitable veins for cannulation or repeated venipuncture. Part 4 only: Healthy female participants of non-childbearing potential aged 18 to 75 years with suitable veins for cannulation or repeated venipuncture.
  3. All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  4. Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
  5. Sexually active fertile male participants with partners of childbearing potential must adhere to the methods detailed in Appendix C 2.1 from the time of first administration of AZD0780 administration until 3 months after the study Follow-up Visit.
  6. Have a between 18 and 35 kg/m2 inclusive and weight at least 50 kg at the Screening Visit and on admission to the Clinical Unit.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any prior gastrointestinal surgery which may affect absorption, eg, gastric bypass or resection.
  4. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  5. Any laboratory values with the following deviations at the Screening Visit or on admission to the Clinical Unit. Abnormal values may be repeated once at the discretion of the Investigator.
  6. Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results other than those described under exclusion criterion number 5, at screening and/or admission to the Clinical Unit, as judged by the Investigator. Abnormal values may be repeated once at the discretion of the Investigator.
  7. Any positive result at Screening for serum , HBcAb, , or .
  8. Any clinically significant abnormal findings in abnormal vital signs, after at least 10 minutes supine rest, at Screening and on admission to the Clinical Unit, as judged by the Investigator. Abnormal values may be repeated once at the discretion of the Investigator..
  9. Any clinically important abnormalities in rhythm, conduction or morphology of the resting and any clinically important abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of changes.
  10. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months prior to screening.
  11. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the Investigator.
  12. Positive screen for drugs of abuse, alcohol, or cotinine at Screening or on admission to the Clinical Unit.
  13. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780, itraconazole (Part 1 only), carbamazepine (Part 2 only), midazolam (Part 3 only), or EE/LNG (Part 4 only).
  14. Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) defined as the regular consumption of more than 500 mg of caffeine per day (eg, > 5 cups of coffee [one cup \~100 mg caffeine]; one cup of tea \~30 mg caffeine) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the Clinical Unit.
  15. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.
  16. Use of any prescribed or nonprescribed medication including hormone replacement therapy, antacids or acid reducing agents (including proton pump inhibitors),analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life.
  17. Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  18. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of the first administration of the study intervention in this study. NOTE: participants consented and screened, but not enrolled/randomized in this study or a previous Phase I study, are not excluded. NOTE: All follow-up activities in a previous research study (including last study visit, unresolved AEs, or abnormal laboratory values) have to be completed prior to the Screening Visit. NOTE: Participants must be checked in VCT in the USA.
  19. Participants who have previously received AZD0780 within 60 days prior to Screening.
  20. Current/previous use of drugs that reduce or inhibit PCSK9 (approved or ; within 12 months of enrolment). Any current/previous use of inclisiran.
  21. Elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs.
  22. Known or confirmed for HLA-A*3101 and/or HLA-B*1502 allele at Screening (Part 2 only).
  23. Participant who previously experienced hypersensitivity reaction to anticonvulsants including phenytoin, primidone, and phenobarbital.
  24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the Clinical Unit).
  25. Judgment by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  26. Participants who are vegans or have medical dietary restrictions.
  27. Participants who cannot communicate reliably with the Investigator.
  28. Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Itraconazole Cohort

    * All participants will receive 2 single doses of dose 1 of AZD0780 and 14 doses of itraconazole, under fed conditions. * This part will consist of Period 1 (AZD0780 administration only), Period 2 (itraconazole administration only), and Period 3 (AZD0780 + itraconazole administration).

    Drug: AZD0780 · Drug: Itraconazole

  • Experimental
    Carbamazepine Cohort

    * All participants will receive 2 single doses of dose 1 of AZD0780 and 6 doses of 100 mg, 6 doses of 200 mg, and 40 doses of 300 mg carbamazepine, under fed conditions. * This part will consist of Period 1 (AZD0780 administration only), Period 2 (carbamazepine administration only), and Period 3 (AZD0780 + carbamazepine administration)

    Drug: AZD0780 · Drug: Carbamazepine

  • Experimental
    Midazolam Cohort

    * All participants will receive 10 single doses of AZD0780 dose 2 and 2 doses of midazolam. On midazolam dosing days, participants will receive midazolam under fasted conditions. * This part will consist of Period 1 (midazolam administration only), Period 2 (AZD0780 administration only), and Period 3 (AZD0780 + midazolam administration).

    Drug: AZD0780 · Drug: Midazolam

  • Experimental
    EE and LNG Cohort

    * All participants will receive 15 single doses of AZD0780 dose 2 and 2 doses of EE and LNG. On EE and LNG dosing days, participants will receive EE and LNG under fasted conditions. * This part will consist of Period 1 (EE and LNG administration only), Period 2 (AZD0780 administration only), and Period 3 (AZD0780 + EE and LNG administration).

    Drug: AZD0780 · Drug: Ethinyl estradiol/levonorgestrel

Interventions

  • Dose 1 and Dose 2

  • * Period 2 (itraconazole administration only). * Period 3 (AZD0780 + itraconazole administration).

  • * Period 2 (carbamazepine administration only). * Period 3 (AZD0780 + carbamazepine administration only).

  • * Period 1 (midazolam administration only). * Period 3 (AZD0780 + midazolam administration).

  • DrugEthinyl estradiol/levonorgestrel

    * Period 1 (EE and LNG administration only). * Period 3 (AZD0780 + EE and LNG administration).

06

What researchers measure

Primary outcomes

  1. AUCinf (Area under concentration-time curve from time 0 to infinity)

    To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  2. AUClast (Area under concentration curve from time 0 to the last quantifiable concentration)

    To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  3. Cmax (Maximum observed drug concentration)

    To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  4. AUCinf

    To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

  5. AUClast

    To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

  6. Cmax

    To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

Secondary outcomes

  1. CL/F (Apparent total body clearance)

    To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  2. t½λz (Terminal elimination half-life)

    To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  3. tmax (Time to reach maximum observed concentration)

    To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  4. Vz/F (Apparent volume of distribution based on the terminal phase)

    To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.

    Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)

  5. Number of participants with Adverse Events and Serious Adverse Events (AEs and SAEs)

    To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.

    Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)

  6. Number of participants with treatment emergent abnormal ECGs

    To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.

    Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)

  7. Vital signs and laboratory test results

    To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.

    Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)

  8. CL/F

    To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

  9. t½λz

    To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

  10. tmax

    TTo describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

  11. Vz/F

    To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.

    Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Feb 2025, 4 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 4 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Nov 4, 2024
StartActual
Sep 25, 2024
Primary completionActual
Feb 17, 2025
CompletionActual
Feb 17, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06671405
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Sep 25, 2024
Primary completion
Feb 17, 2025
Completion
Feb 17, 2025
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion